Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients

Published:2019-08-30 Issue:10 Volume:71 Page:1670-1680
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Cassia Matthias A.¹,Alberici Federico¹^ORCID,Jones Rachel B.²,Smith Rona M.²,Casazza Giovanni³,Urban Maria L.⁴,Emmi Giacomo⁴^ORCID,Moroni Gabriella⁵,Sinico Renato A.⁶,Messa Piergiorgio⁷,Hall Frances⁸,Vaglio Augusto⁴,Gallieni Maurizio⁹,Jayne David R.²

Affiliation:

1. ASST Santi Paolo e Carlo and the University of Milan Milan Italy

2. University of Cambridge Cambridge UK

3. University of Milan Milan Italy

4. University of Florence Florence Italy

5. Fondazione IRCCS Ca’ Granda Ospedale Maggiore di Milan Milan Italy

6. University of Milan Bicocca Milan Italy

7. Fondazione IRCCS Ca’ Granda Ospedale Maggiore di Milan and University of Milan Milan Italy

8. Cambridge University Hospital Cambridge UK

9. University of Milan and ASST Fatebenefratelli Sacco Milan Italy

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40932

Reference37 articles.

1. Lupus nephritis and B-cell targeting therapy

2. New insights into the immunopathogenesis of systemic lupus erythematosus

3. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

4. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

5. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update;Seminars in Arthritis and Rheumatism;2024-04

2. Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus;Lupus Science & Medicine;2024-01

3. Biologische Therapie bei systemischem Lupus erythematodes, Antiphospholipid-Syndrom und Sjögren-Syndrom: evidenz- und praxisbasierte Leitlinien;Kompass Autoimmun;2024

4. Hypogammaglobulinemia and severe infection risk in patients with autoimmune diseases during rituximab treatment;Ulusal Romatoloji Dergisi;2023-11-27

5. Risk Factors and Incidence of Serious Infections in Patients With Systemic Lupus Erythematosus Undergoing Rituximab Therapy;The Journal of Rheumatology;2023-10-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3